Constellation Pharmaceuticals welcomes Dr Scott Braunstein to its Board of Directors

– USA, MA –  Constellation Pharmaceuticals, Inc. (Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Scott Braunstein, M.D., has been appointed to its Board of Directors.

“We welcome Scott to Constellation’s board,” said Jigar Raythatha, President and Chief Executive Officer of Constellation Pharmaceuticals.  “He has a wealth of experience as an executive and board member in the biopharmaceutical industry and as a healthcare investor and practicing physician. This experience will help our Company considerably as we advance toward our goal of becoming a late-stage oncology development company.”

About Dr Scott Braunstein

Dr. Braunstein joins Constellation’s team with a track record of growing emerging and established biopharmaceutical companies as an investor and a pharmaceutical executive.  He is currently chairman of the board of directors of ArTara Therapeutics and a member of the board of directors of several public and private companies, including Esperion Therapeutics, Marinus Pharmaceuticals, SiteOne Therapeutics, Trevena, and Ziopharm Oncology.  Previously he served as chief operating officer at Pacira Pharmaceuticals.  Prior to joining Pacira, Dr. Braunstein was a healthcare portfolio manager at Everpoint Asset Management.  He spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team and as a portfolio manager in the Global Healthcare team.  He is currently an operating partner at Aisling Capital.  Dr. Braunstein began his career as a physician and earned his medical degree from the Albert Einstein College of Medicine.

“I’m thrilled to be joining the Constellation board at this time of growth,” said Dr. Braunstein. “The Company has a strong epigenetics platform and encouraging preliminary clinical data from its lead programs in key areas of unmet need for myelofibrosis and prostate cancer patients.  I look forward to helping Constellation in what we expect to be an exciting year of data.”

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers as well as the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>